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Abstract 
Over the last few years, several groups have evaluated the potential of microRNAs 
(miRNAs) as biomarkers for cardiometabolic disease. In this review, we discuss the 
emerging literature on the role of miRNAs and other small noncoding RNAs in platelets 
and in the circulation, and the potential use of miRNAs as biomarkers for platelet 
activation. Platelets are a major source of miRNAs, YRNAs, and circular RNAs. By 
harnessing multiomics approaches, we may gain valuable insights into their potential 
function. Because not all miRNAs are detectable in the circulation, we also created a 
gene ontology annotation for circulating miRNAs using the gene ontology term 
extracellular space as part of blood plasma. Finally, we share key insights for 
measuring circulating miRNAs. We propose ways to standardize miRNA 
measurements, in particular by using platelet-poor plasma to avoid confounding 
caused by residual platelets in plasma or by adding RNase inhibitors to serum to 
reduce degradation. This should enhance comparability of miRNA measurements 
across different cohorts. We provide recommendations for future miRNA biomarker 
studies, emphasizing the need for accurate interpretation within a biological and 
methodological context.  
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circRNAs  - circular RNAs 
Ct  - cycle threshold  
GO  - gene ontology  
lncRNAs -  long non-coding RNAs  
miRNA -  microRNA 
MP  - microparticle 
mRNA - messenger RNA 
NGS   - next-generation sequencing 
PCPT  - phosphatidylcholine transfer protein 
PPP  -  platelet-poor plasma  
PRP   - platelet-rich plasma 
qPCR  - quantitative polymerase chain reaction 
rRNA  - ribosomal RNA 
  
Introduction 
Platelets play a key role in hemostasis, initiating and propagating 
thrombosis.1Dysregulation and inappropriate activation of platelets underpin a wide 
range of important diseases, including stroke and myocardial infarction, whereas 
impairment of platelet function results in bleeding disorders. Platelets are anucleate 
and were previously considered to be simple cytoplasmic fragments of 
megakaryocytes. We now know that platelets house an array of molecules, including 
proteins, RNA, and the subcellular machinery of de novo protein synthesis. Platelets 
can synthesize new proteins, such as the integrin alpha3 (glycoprotein-IIIa) protein 
and the fibrinogen receptor.2,3 They contain messenger RNA (mRNA), which codes 
for around a third of human genes.4,5 More recently, the discoveries that platelets are 
an abundant source of microRNAs (miRNA),6 and that miRNA expression profiles 
within platelets correlate with platelet reactivity,7 raised the exciting possibility of novel 
therapeutic targets and disease biomarkers. 
Initial studies by Mitchell et al8 revealed that not all miRNAs in the circulation are 
intracellular. This pool of extracellular circulating miRNA consists of miRNA within 
microvesicles, exosomes, or bound to proteins. The finding that miRNAs can also be 
measured in cell-free serum and plasma was surprising, given their high RNase 
activity. Compared with mRNAs, miRNAs remain relatively stable in the circulation 
through several protective mechanisms: association with RNA-binding proteins and 
lipoproteins, or housing in shed microvesicles, such as exosomes or microparticles 
(MPs).9–12 Platelets release MPs, particularly during activation. These vesicles contain 
a host of proteins, inflammatory mediators, and noncoding RNAs.13–15 Microvesicles 
might be taken up by other cells, introducing another layer of complexity in terms of 
intercellular signaling by potentially allowing direct regulation of the recipient cell’s 
mRNA profile and gene expression.16,17Given this emerging role for circulating 
miRNAs, plasma and serum miRNA profiles may find use in clinical practice as novel 
markers of disease, organ function, and prognosis.18 
In this review, we bring together nearly a decade’s experience with circulating 
noncoding RNAs, with particular focus on platelet-derived and associated miRNAs, 
YRNAs, long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs). We 
conducted a literature search in PubMed as queried on November 23, 2016, using the 
search terms “platelet* AND (miRNA [MeSH Terms] OR micro RNA [MeSH Terms] 
OR micro-RNA OR microRNA)”. Four hundred and thirty-four results were retrieved, 
of which 75 were relevant primary research papers and 39 were relevant literature 
reviews. From the literature to date, we collate the known platelet repertoire of 
noncoding RNAs and contemplate their physiological significance. We also examine 
their disease associations and potential clinical applications. Finally, we discuss the 
practical challenges in measuring and comparing miRNA levels, highlighting obstacles 
that will need to be overcome for this relatively new field to come of age. 
Noncoding RNAs in Platelets and the Circulation 
Different noncoding RNAs have been described (Figure 1).  
miRNAs 
The human genome codes for small (≈22 nucleotide) regulatory RNA molecules, 
termed miRNAs or miRs. Since miRNAs were first discovered in 1993, over 2500 have 
been defined.19,20 They are highly evolutionarily conserved and important in the 
posttranscriptional regulation of protein expression—about one third to half of the 
human genes are estimated to be regulated by miRNAs.21–23 MiRNAs act by imperfect 
Watson–Crick base pairing to the 3′untranslated region (UTR) of target mRNA to affect 
translation or induce degradation.24,25 MiRNAs can be expressed as stand-alone 
scripts or alongside the parent gene mRNA. In either case, the primary miRNA 
transcript is processed by the nuclear microprocessor complex consisting of the 
endoribonuclease Drosha and the double-stranded RNA-binding protein 
Pasha/DGCR8.26,27 The resultant hairpin pre-miRNA is then transferred to the 
cytoplasm by the nuclear membrane protein exportin-5 and further processed by the 
endoribonuclease Dicer.28 The resulting mature miRNA duplex associates with an 
Argonaute (Ago) protein, which unwinds the double strand and incorporates one of 
the 2 complementary miRNA strands, forming the RNA-induced silencing 
complex.29 The RNA-induced silencing complex stabilizes the miRNA strand and 
guides it to its target mRNA. Because platelets do not have a nucleus and thus cannot 
transcribe miRNAs, it is currently thought that they inherit their miRNA content during 
the shedding process from megakaryocytes.30 Thus, the platelet miRNAome in the 
circulation may provide insights into megakaryocyte function in the bone marrow. 
There are many more miRNAs encoded in the human genome than there are 
detectable in the circulation.31 For example, we detected >200 miRNAs using next-
generation sequencing (NGS) in plasma samples.32 Detectable miRNAs greatly vary 
in abundance. Not all miRNAs that are present in the circulation can be consistently 
quantified with cycle threshold (Ct) values of <32 by quantitative polymerase chain 
reaction (qPCR), even after preamplification. Another striking observation is the high 
correlation among the abundant circulating miRNAs.33 This may be because of their 
common platelet origin: in response to antiplatelet drugs, circulating levels of many 
miRNAs are reduced in platelet-poor plasma (PPP).34 Research into miRNAs is 
hampered by the current lack of functional miRNA data in bioinformatics resources. 
Access to cataloged experimental data is crucial to enable simple questions to be 
asked, such as, Which miRNAs are present in the circulation?, as well as the ability to 
perform sophisticated pathway and network analyses.35 This lack of freely accessible 
data is being addressed by the addition of gene ontology (GO) annotations for 
cardiovascular-related miRNAs.36,37 To answer the question of circulatory miRNAs, we 
have created GO annotations for those miRNAs identified as being present in human 
plasma from our previous study.32 In the parlance of GO, the annotations were created 
using the GO term extracellular space (GO:0005615) with the addition of contextual 
information describing the extracellular space as part of blood plasma (using the Uber 
Ontology term Uberon:0001969). A large number of miRNAs were identified in PPP 
and platelet-rich plasma (PRP).32 For those with marked enrichment in PRP, as well 
as significantly increased levels in a platelet spike-in experiment, we were additionally 
able to include in the annotation that the miRNAs present in the extracellular space 
are likely to have originated from platelets (using the cell ontology term CL:0000233). 
In total, we have identified 230 human miRNAs as present in the circulation, and the 
annotations providing this information are available in the GO database.38 Inclusion of 
functional annotations such as these into public databases will enable researchers to 
find and analyze miRNA data more easily, allowing for faster progression of their 
research. 
YRNAs 
In our most recent study, we have also identified YRNAs as another species of 
circulating noncoding RNAs that is platelet-derived.32 YRNAs are small noncoding 
RNAs, ≈100 nucleotides in length, that originate from 4 human genes 
(RNY1, RNY3, RNY4, and RNY5and ≈900 pseudogenes).39,40 Using NGS in PPP and 
PRP, we observed a dominant peak at sequences of 32 to 33 nucleotides long, which 
was mapped to YRNA genes (Figure 2A).32The full-length YRNAs have cytoplasmic 
or nuclear localization and are involved in the initiation of DNA replication, as well as 
in ribosomal RNA quality control.41,42 They are components of Ro ribonucleoproteins, 
which constitute important autoantigens in autoimmune diseases, such as systemic 
lupus erythematosus and Sjögren’s syndrome.43YRNA fragments are present in the 
circulation, with 5′ fragments being much more abundant than 3′ fragments for the 
majority of RNY genes.32,44 YRNA fragments are generated during cell stress or 
apoptosis. Given that YRNA fragments are abundant in platelets, and strongly 
correlate to platelet-derived proteins in the circulation (Figure 2B),32we speculate that 
the YRNA fragments are formed during the budding of platelets from megakaryocytes. 
In contrast to the processing of mature miRNAs from precursor miRNAs, YRNA 
fragments are generated by a Dicer-independent mechanism.45 Unlike miRNAs, we 
also failed to detect YRNAs in Ago2 complexes of MEG-01 cells, a human 
megakaryoblastic cell line.32 The predominant platelet origin of YRNA fragments in 
human plasma is further supported by the results from platelet spike-in experiments.32 
Ribosomal RNA 
Ribosomal RNA is a key regulator of intracellular protein synthesis and is also detected 
in the circulation. Tissue damage and unregulated cell death result in significant 
quantities of ribosomal RNA shifting into the extracellular compartment.46,47 As 
reviewed recently,48extracellular ribosomal RNA may have several important 
pathophysiological roles in atherosclerotic plaques, including promotion of vascular 
hyperpermeability, initiation of coagulation and thrombus formation, recruitment of 
leukocytes, promotion of a proinflammatory phenotype of monocytes/macrophages, 
and promotion of cardiomyocyte death. 
Long Noncoding RNAs 
Recently, attention has shifted from small noncoding to lncRNAs. Unlike miRNAs and 
YRNA fragments, which are mainly found in the cytosol, lncRNAs are predominantly 
retained in the nucleus.49 This nuclear localization has important implications for their 
release mechanism. Although miRNAs and YRNA fragments are secreted as part of 
any budding process of microvesicles with cytoplasmic components, even in the 
absence of injury, the secretion of lncRNAs may be dependent on cellular damage 
that is sufficient to release nuclear material. On release, the lncRNAs require 
protection from RNase degradation. In general, lncRNAs may be more susceptible to 
RNase activity than small noncoding RNAs because the longer sequence is more 
vulnerable to cleavage and not as easily complexed and protected by RNA-binding 
proteins. Although lncRNAs are readily detected in whole blood, levels in plasma or 
serum tend to be low, at least in healthy individuals without tissue injury. The release 
of mitochondria-associated lncRNAs has been described in patients with myocardial 
infarction.50 It is possible that mitochondrial lncRNAs are protected from RNase 
degradation. Further, because cardiomyocytes are particularly rich in mitochondria, 
these lncRNAs may indeed be cardiac-derived. However, unlike troponins, lncRNAs 
are not cardiac muscle-specific, so contributions from other cell types cannot be 
excluded.51Because platelets are anuclear and have a low mitochondrial content, most 
lncRNAs may not be detectable in platelets, with the notable exception of circRNAs. 
Circular RNAs 
Recent evidence suggests that platelets are relatively abundant in circRNAs,52 an 
emerging class of noncoding RNAs that had been described as early as 
1976.53 Development of advanced NGS techniques led to their recent 
rediscovery,54 showing ubiquitous expression in both humans and mice.55 Several 
pathways exist to generate circRNAs.56 Most commonly, they are derived from exons 
of protein-coding genes through back-splicing, whereas some arise from intronic or 
intergenic regions via alternative splicing. circRNAs are generally localized in the 
cytoplasm, but how they are exported from the nucleus remains unknown. RNA-
binding proteins like Quaking and Muscleblind are thought to affect the abundance of 
circRNAs in human cells through binding of the specific RNA-binding proteins to 
flanking intronic sequence motifs. Interaction between the RNA-binding proteins on 
each end approximates both ends of the exon and facilitates the formation of a circle. 
Quaking regulates human circRNA biogenesis, and knockdown of Quaking decreases 
the expression of abundant circRNAs.57 CircRNAs were found to be enriched in 
platelets, where they are generated by exon back-splicing.52 Using RNase R to 
selectively remove linear transcripts, several distinct circRNAs were identified in 
platelets. Although the majority of circRNAs are not cell type-specific, human platelets 
and erythrocytes were found to be highly enriched for circRNAs compared with 
nucleated cell types. Several circRNAs were expressed at much higher levels than the 
linear form of the RNA in platelets and erythrocytes. Interestingly, the relative 
proportion of circRNAs in cultured megakaryocytes is much lower compared with 
mature platelets. Combined with the finding that circRNA decays at a significantly 
slower rate than linear RNA, and platelets lose >90% of their progenitor mRNA, the 
enrichment of circRNA in platelets might be the result of linear RNA 
degradation.52 This process has a profound effect on the composition of RNA because 
anucleate platelets cannot transcribe new RNA. Recent reports demonstrated that 
circRNAs can serve as miRNA sponges, which are believed to negatively regulate 
miRNAs by sequestering miRNA molecules.58 This raises questions of how circRNAs 
interact with miRNAs and mRNAs in platelets and how circRNA transcripts are formed 
in platelets. With their enrichment being a signature of mRNA decay, platelet circRNAs 
may reflect platelet function or ageing. 
miRNA Repertoire of Platelets 
Landry et al6 first reported a large number of platelet miRNAs by using locked nucleic 
acid–based microarray profiling. NGS has enabled the discovery of novel miRNA 
species. Plé et al59 identified nearly 500 species, with the let-7 family of miRNAs 
comprising nearly 50% of the total. Since then, Bray et al4 have identified many more, 
bringing the total of recognized platelet miRNAs to ≈750. The variation in reported 
platelet miRNA expression is not solely because of interindividual differences, such as 
sex and age.60 Sample preparation, storage, normalization procedures, and 
measurement platforms play an important role. Studies aimed at defining the platelet 
miRNA profile use a variety of techniques, including microarrays, qPCR-based 
methods, and NGS. For example, Wang et al61 demonstrated platform-associated 
amplification differences in miR-107, which showed much higher amplification with 
locked nucleic acid–based assays compared with TaqMan assays. In clinical 
laboratory conditions, Yu et al62 showed upregulation of several apoptosis-related 
platelet miRNAs after prolonged blood bank storage of platelets. As platelet 
preparation from whole blood can lead to contamination with leukocytes and 
erythrocytes, themselves abundant sources of miRNAs, controlling cellular 
contamination of platelet preparations is essential.61 Variation in preparation and 
storage conditions can drastically affect platelet miRNA expression, which may explain 
why interstudy miRNA expression ranks are highly variable. Based on the current 
literature, a combined interstudy miRNA expression rank list is presented in Figure 3. 
Association of Platelet miRNAs With Disease 
Antiplatelet drugs reduce the risk of cardiovascular events, but patients on antiplatelet 
therapy still suffer thrombotic events. Ever more potent antiplatelet strategies carry the 
risk of bleeding complications. Ideally, a so-called “sweet spot” could be defined for 
each patient, which offers maximum platelet inhibition with minimal bleeding risk.63 For 
optimal platelet inhibition, platelet turnover is important: with a life span of 7 to 9 days, 
10% to 15% of the platelet pool must be replenished every day, equivalent to 1010 to 
1011 platelets per day.64 The platelet turnover rate may be important for the efficiency 
of drugs like aspirin with a short half-life. Aspirin irreversibly binds cyclooxygenase, so 
is effective for the full life span of the platelet. However, increased platelet turnover 
can lead to budding of new platelets without inactive cyclooxygenase between doses. 
Furthermore, newly formed platelets are larger, more reticulated, more reactive, and 
more prone to participate in thrombus formation compared with older platelets. They 
also contain a higher amount of RNA and are more able to produce proteins, in 
particular, alpha granule proteins. Counting the subset of reticulated platelets may be 
a parameter for platelet turnover. However, the intrinsic properties of platelets could 
be even more important for platelet reactivity than their turnover rate.65 In light of the 
enrichment of miRNAs and circRNAs, and the described effects of mRNA degradation 
during the lifetime of platelets, the noncoding RNA content of platelets may better 
reflect their intrinsic properties. 
Platelet miRNA expression profiles in healthy volunteers remain stable over the life-
span of a platelet.66 This expression profile is significantly altered in various disease 
states, including myocardial infarction,67,68 diabetes mellitus,69 and cancer.70 There is, 
therefore, the opportunity to find new biomarkers or therapeutic targets and increase 
our understanding of the pathophysiological mechanisms of these diseases. 
Anucleate platelets lack transcriptional control, so differences in miRNA signatures 
during platelet-activating disease states have been ascribed to several mechanisms: 
shedding of MPs,71 synthesis of mature miRNA from precursor miRNAs,69 and 
posttranscriptional modifications.59 We undertook the first systematic analysis of 
circulating miRNAs in a large population-based study (the Bruneck study) and 
revealed a loss of miRNAs in type 2 diabetes mellitus.72 Subsequent studies indicated 
that this loss may be attributed to activation of calpain, which can affect platelet levels 
of Dicer.73 Because this endoribonuclease is key in the processing of precursor 
miRNAs to mature miRNAs, its loss resulted in decreased levels of several platelet-
enriched miRNAs.69,74 These findings are in line with studies showing that circulating 
miRNA changes in cardiovascular risk can be attributed to platelets.32,34Additionally, 
we demonstrated that a combination of miRNAs may predict future cardiovascular 
events.75 This has been confirmed by other investigators.76 In continuation of our work 
on circulating miRNAs in diabetes mellitus,72 we have identified 2 angiogenic miRNAs 
as biomarkers for diabetic retinopathy.77 
Findings by other investigators and our group suggest that platelet miRNAs might not 
only reflect but also affect platelet function. 
miR-96 and Vesicle-Associated Membrane Protein 8 
In 2010, Kondkar et al78 reported a role for miR-96 in platelet reactivity. They showed 
that miR-96 may act through regulation of vesicle-associated membrane protein 8 
(VAMP8), an important SNARE protein involved in platelet degranulation. Healthy 
volunteers’ platelets were categorized as either hyper- or hyporeactive. mRNA 
profiling revealed differential expression of a range of scripts, including VAMP8 mRNA 
(4.8-fold decrease in the hyporeactive versus hyper-reactive platelets). This translated 
to a 2.5-fold lower VAMP8 protein expression in the hyporeactive platelets. miR-96 
levels were upregulated in the hyporeactive platelets (2.6-fold higher). Transfection of 
VAMP8-expressing human colorectal cancer cells with miR-96 was associated with 
dose-dependent reductions in VAMP8 mRNA and protein levels; a similar finding was 
reported in cells of a megakaryocyte lineage. miR-96 was predicted to bind the 3′UTR 
of VAMP8. In contrast with this study, Shi et al79reported no association between 
platelet response to clopidogrel and miR-96 expression, and miR-96 was not among 
the most highly expressed miRNAs found in human platelets. Although this does not 
discredit a role for miR-96 in regulating platelet reactivity, these findings need to be 
validated and explained in a larger study. 
MiR-376c, miR-599, and Platelet Phosphatidylcholine Transfer Protein 
There is a racial disparity in survival in coronary heart disease between patients with 
Caucasian and Afro-Caribbean background, even after adjusting for all known factors. 
Edelstein et al80 investigated whether racial differences in platelet function underpin 
an increased thrombotic risk. One hundred and fifty-four healthy black and white 
volunteers were recruited, and platelet reactivity to thrombin was measured. Higher 
aggregation and platelet calcium responses to PAR4-AP (thrombin receptor 4 
activating peptide) in Afro-Caribbean individuals were found. PCTP 
(phosphatidylcholine transfer protein)–encoding mRNA was found to be upregulated 
in Afro-Caribbeans. After profiling platelet miRNA signatures, 178 miRNAs, including 
miR-376c, were predicted to target PCTP mRNA. miR-376c levels inversely correlated 
with PCTP mRNA levels, PCTP protein levels, and PAR4 reactivity. miR-376c is part 
of a cluster of miRNAs differentially expressed by ethnic origin, which may underpin 
differences in platelet function. Interestingly, a statistical cluster of 24 miRNAs all 
mapped to chromosome 14q32.2. Among other differentially expressed miRNAs were 
some of the most abundant platelet miRNAs: miR-223, miR-21, miR-23b, miR-107, 
and let-7c. Plé et al81 also found evidence of miRNA regulation of PCTP. Their analysis 
predicted miR-599 targeting of the 3′UTR of PCTP mRNA and showed downregulation 
of a reporter gene containing the PCTP 3′UTR in HEK293 (human embryonic kidney) 
cells transfected with pre-miR-599. 
miR-223 and P2Y12 Receptor Expression 
miR-223 is highly expressed in platelets and megakaryocytes, where it is thought to 
regulate thrombopoiesis. One of the most interesting features of miR-223 is its ability 
to bind to the 3′UTR of human P2Y12 receptor mRNA.6 The P2Y12 receptor mediates 
important platelet functions, including aggregation and granule secretion, and is 
activated by ADP, the physiological agonist of this Gi2 protein-coupled receptor. 
Landry et al6 showed that platelet P2Y12 receptor mRNA coprecipitates with Ago2, 
suggesting that miR-223 could regulate receptor levels and, thereby, platelet function. 
Platelet response to ADP antagonists is clinically relevant given the widespread use 
of drugs such as clopidogrel, prasugrel, and ticagrelor in the treatment of myocardial 
infarction and ischemic stroke. 
Because of the proposed regulation of P2Y12 receptor function, miR-223 has been the 
focus of many clinically orientated studies. In particular, there is great interest in 
relation to platelet responsiveness to clopidogrel, a prodrug that requires hepatic 
cytochrome P450 enzymes to become active. Shi et al79 reported decreased levels of 
platelet miR-223 in association with high platelet reactivity, despite treatment with 
clopidogrel. They looked at patients presenting with non–ST-elevation acute coronary 
syndrome, in terms of their platelet reactivity index, who were treated with aspirin and 
clopidogrel. In patients who had a reduced response to clopidogrel, platelet miR-223 
was significantly downregulated, whereas miR-96 was unchanged. Platelet miR-223 
also inversely correlated with the platelet reactivity index. Of note, neither miR-223 nor 
miR-96 were significantly different between normal and low responders when ADP-
induced platelet aggregometry was used. These results suggest that platelet miR-223 
may be a predictor of normal and low responders to clopidogrel. This is supported by 
the fact that P2Y12 mRNA can be found in Ago2 immunoprecipitates.6 
In a preliminary report including 21 males presenting with non–ST-elevation acute 
coronary syndrome, Chyrchel et al82 studied miR-223 plasma levels. Patients were 
treated with aspirin plus either clopidogrel, prasugrel, or ticagrelor. Although there 
were no differences in plasma miR-223 levels between drug types, when all the data 
were pooled, miR-223 positively correlated with the level of platelet inhibition.82 These 
results seem in line with those of Shi et al79 who found that high platelet miR-223 levels 
predicted efficacious platelet inhibition with clopidogrel. Similarly, Zhang et al83 report 
decreased plasma miR-223 to be associated with clopidogrel low responders. In this 
study of 62 patients with unstable angina, miR-223 was found to be the only 
independent predictor of low responders to clopidogrel and was higher with greater 
degrees of platelet inhibition. 
miR-223 is also expressed in mouse platelets. In response to high agonist 
concentrations, miR-223 knockout mice do not show any detectable alteration in 
aggregation, speed of clot retraction, platelet adhesion, or bleeding time. P2Y12 mRNA 
expression levels are also unchanged.84 This is probably because of mouse 
P2Y12 mRNA lacking the specific binding site for miR-223, rendering mouse models 
difficult to interpret in this context. Nonetheless, Elgheznawy et al69 subsequently 
demonstrated that miR-223 deletion in mice did result in modestly higher platelet 
activation at lower agonist concentrations. Proteomic analysis revealed differential 
expression of kindlin-3 and coagulation factor XIII-A in platelets from miR-223-
deficient mice. 
Zampetaki et al75 found that serum miR-223 levels are inversely associated with risk 
of future myocardial infarction and showed a stronger association with fatal than 
nonfatal events. Badrnya et al85 showed reduced platelet microvesicle miR-223 in 
smokers. These findings are potentially complementary to those relating low platelet 
miR-223 level to increased P2Y12 activity in humans and to those showing higher 
platelet reactivity in response to miR-223 deletion in mice. Subsequent clinical studies 
have investigated platelet miR-223, including in a small cohort of patients who suffered 
an ischemic stroke. Duan et al86 report that platelet miR-223 and miR-146a were lower 
in stroke patients with diabetes mellitus versus controls. Platelet miR-223 and miR-
146a levels significantly correlated with platelet reactivity as measured by P-selectin 
expression and also correlated to plasma levels, suggesting that platelets are a major 
source of circulating miR-223. 
In summary, miR-223 targets the 3′UTR of the human P2Y12 platelet receptor mRNA. 
The P2Y12 receptor is important in platelet activation and is the target of many drugs 
used to inhibit platelet function. Lower levels of platelet miR-223, therefore, may result 
in more P2Y12 receptor activity and, thus, higher platelet reactivity. In this way, lower 
platelet miR-223 levels may increase the risk of thrombotic disease, such as 
myocardial infarction. This also may underpin the observation that lower platelet miR-
223 levels are associated with reduced efficacy of P2Y12 receptor antagonists, such 
as clopidogrel. Mice lack the specific miR-223-binding site on the P2Y12 mRNA, and 
so comparisons to human data is difficult. Nonetheless, miR-223-deficient mice do 
seem to have altered platelet function, perhaps through regulation of other proteins. 
miR-126 and ADAM9 (A Disintegrin and Metalloproteinase Domain-Containing 
Protein 9) 
Early studies, including one from our group,72 stated that miR-126 is endothelial 
specific. Although miR-126 is enriched in endothelial cells and supports endothelial 
integrity, its circulating levels cannot be attributed solely to endothelial cells. In fact, 
megakaryocytes and endothelial cells both express miR-126, and circulating miR-126 
levels seem to be predominantly platelet derived.34,77 
de Boer et al87 investigated the effects of aspirin on the platelet contribution of 
circulating miR-126 in patients with type 2 diabetes mellitus. PRP from subjects was 
treated with either arachidonic acid (a platelet activator) or arachidonic acid plus 
aspirin. Once the PRP had been treated, it was centrifuged to separate the platelets 
from the now PPP. Platelet activation resulted in a considerable transfer of miR-126 
to the PPP fraction, and this could be rescued with the addition of aspirin. miR-223, 
miR-16, and miR-423 showed a similar pattern, suggesting that they are all released 
from platelets on activation and that aspirin attenuates this release. miR-126 levels 
also correlated with platelet activation as measured by soluble P-selectin. As part of 
another clinical trial involving patients with type 2 diabetes mellitus, the platelet 
activation state (measured via P-selectin expression) was assessed in 40 patients 
treated with increasing doses of aspirin. Platelet activation positively correlated with 
plasma miR-126 and aspirin reduced circulating levels of miRNA-126. Arguing against 
an endothelial origin of miR-126, the authors point out that aspirin primarily inhibits 
platelet-enriched COX-1, whereas the endothelium predominantly expresses COX-2. 
They also demonstrated no change in circulating von Willebrand factor.87 Taken 
together, these findings suggest that aspirin has the potential to significantly alter the 
miRNA signature of plasma, and careful consideration should be given when 
designing clinical studies in pursuit of novel biomarkers. 
In our experiments, we demonstrated that plasma miR-126 levels (1) correlate to 
platelet MPs, (2) are reduced on platelet inhibition, and (3) are associated with markers 
of platelet activation in the general population.32 These associations were further 
substantiated by genetic evidence. The single nucleotide polymorphism rs4636297 is 
located in the primary transcript-encoding region of miR-126 and affects its processing 
to mature miR-126. The minor allele is associated with increased processing of the 
primary miRNA to mature miR-126. In a population-based study, carriers of the minor 
allele had higher levels of miR-126 in plasma and in serum.32 The increase in 
circulating miR-126 was associated with a rise in platelet activation markers, such as 
platelet factor 4 and proplatelet basic protein. The genetic data on miR-126 and 
platelet function were in line with findings in the Bruneck cohort, in which miR-126 
serum levels were positively associated with risk of myocardial infarction after 
adjustment for miR-223 and miR-197, again with platelets being identified as the most 
probable source.75 A study by Yu et al88 showed that higher plasma miR-126 predicted 
major adverse cardiac events in 491 patients after a percutaneous coronary 
intervention, while on dual antiplatelet therapy. 
In mice, inhibition of miR-126 by antagomiRs (synthetic inhibitors of miRNAs) 
decreased thromboxane A2-dependent platelet aggregation. This effect is likely 
because of megakaryocyte miR-126, but because antagomiRs are administered 
systemically, the contribution of other cell types, in particular endothelial cells, cannot 
be excluded. However, inhibition of miR-126 expression in endothelial cells would be 
expected to result in endothelial dysfunction and increased platelet activation. 
Similarly, if the effects of the single nucleotide polymorphism rs4636297 were limited 
to endothelial cells, one might expect that higher miR-126 levels are protective for 
endothelial cells and, thus, reduce platelet activity. The opposite was observed in mice 
and men. In MEG-01 cells, ADAM9 was confirmed as a direct miR-126 target that 
attenuates the adhesion of platelets to collagen. Inhibition of miR-126 by antagomiRs 
also had indirect effects on P2Y12 expression levels, at least in mice. Thus, in addition 
to endothelial cells, miR-126 affects megakaryocytes. It remains to be seen whether 
platelet-specific deletion of miR-126 can recapitulate the accelerated atherosclerosis 
phenotype seen in miR-126-deficient mice.89 
In summary, higher plasma or serum levels of miR-126 are associated with an 
increased risk of myocardial infarction and other major adverse cardiac events. This 
may, at least in part, occur via increased platelet activation. Inhibition of miR-126 with 
antagomiR-126 reduces platelet activation in mice, which may be explained by 
blocking of ADAM9’s negative effect on platelet:collagen adhesion or via indirectly 
affecting platelet P2Y12 expression levels. 
Cellular Crosstalk Via miRNAs? 
Several studies suggest that secreted miRNAs may act as paracrine mediators. The 
concept is appealing, but most evidence is currently limited to in vitro studies. By 
overexpressing a miRNA in one cell type, harvesting microvesicles from the 
conditioned media, and adding these microvesicles to recipient cells, miRNA transfer 
and downregulation of miRNA targets is detectable, suggesting that the miRNA uptake 
has biological function. There are several caveats to these in vitro studies: 
1. MiRNAs are not abundant in the circulation, and preamplification is usually 
required for all but the most abundant miRNAs for reliable detection by qPCR. It 
is difficult to envisage how the few copies of miRNAs would have a potent effect 
on target gene expression. The amount of circulating miRNAs is several orders of 
magnitude below the cellular miRNA content, and exogenous miRNAs would have 
to compete with the endogenous miRNAs in the recipient cells for loading into the 
RNA-induced silencing complex. Unless there is a receptor that recognizes 
miRNAs and initiates a downstream signaling cascade, it is difficult to envisage 
how uptake of exogenous miRNAs could mediate biological effects. 
2. MPs and exosomes are rich in proteins. The protein content of microvesicles may 
be functionally more important than their miRNA load. RNase treatment does not 
unambiguously prove that the observed biological effect is because of miRNAs. 
Protein degradation may also occur during the RNase digestion step. 
3. In situ hybridization studies for a particular miRNA tend to reveal a characteristic 
staining pattern. For example, staining for miR-126 is confined to endothelial cells, 
whereas staining for miR-143 and miR-145 is observed in vascular smooth muscle 
cells. If miRNA transfer was a common phenomenon, such specificity would not 
be detected, and a more homogenous staining pattern would be expected. 
4. Importantly, the tissue architecture, including basement membranes and 
extracellular matrix, should act as a physical barrier for the exchange of 
microvesicles. 
5. Routine cell culture uses fetal calf serum, which is a source of bovine 
microvesicles. 
Thus, we currently lack convincing evidence that the exchange of miRNAs is more 
than an in vitro phenomenon. In uninjured tissues, cellular miRNA exchange might be 
low. It is conceivable that miRNA transfer could occur under pathological conditions, 
such as platelet activation and clearance by inflammatory cells. Several experiments 
shed light on the role of platelet miRNA as a putative paracrine regulator of cellular 
function via regulation of other cells’ mRNA and protein expression. For abundant 
platelet miRNAs, such as miR-223, target genes have been described, many of which 
are associated with inflammation. This miRNA is also expressed in leukocytes, further 
indicating a potential role. Given that platelets are already heavily implicated in several 
disease processes with an inflammatory basis, an interplay between endothelial cells, 
leukocytes, monocytes, and other cell types by endogenous and transferred miRNA 
seems plausible and an important area for further investigation. 
Jansen et al90 sought to define the miRNA content of circulating microvesicles and 
vesicle-free plasma in 176 patients with stable coronary artery disease undergoing 
coronary angiography. Over 6 years follow-up, microvesicle miR-126 and miR-199a 
levels above the median were associated with significantly fewer major adverse 
cardiac events and percutaneous coronary interventions. There was no association 
between miRNAs from PPP and cardiovascular events. Microvesicle miR-126 was 
significantly reduced, and miR-199a trended toward reduction, in coronary artery 
disease patients versus age-matched controls. Again, no such difference was found 
in the PPP. Through microvesicle typing of surface markers, they established that miR-
126 expression is highest in CD31+/CD42b−microvesicles (ie, endothelial), consistent 
with known expression patterns in endothelial cells, and miR-199a is highest in 
CD31+/CD42b+ microvesicles (ie, megakaryocyte-derived). These results are in 
contrast to results for circulating miR-126 levels. However, this study by Jansen et 
al90 looked specifically at the microvesicular compartment, making cross-study 
comparisons difficult. 
Laffont et al17 showed that activated platelets can deliver regulatory Ago2–miRNA 
complexes to endothelial cells and that this occurs via MPs. First, they confirmed that 
activated platelets release substantially more MPs than quiescent platelets. Profiling 
the miRNA content of the MPs showed that the miR-223 content was greatly increased 
after platelet activation, suggesting selective packaging of miRNAs into platelet MPs. 
They then showed that the MPs contain functional Ago2:miR-223 complexes, which 
could cleave a complementary miR-223 RNA sensor, suggesting that these 
complexes are functionally relevant. Next, they used fluorescently labeled MPs to 
demonstrate internalization by human umbilical vein endothelial cells. Endothelial 
miR-223 levels increased 22-fold after incubation with MPs for 1 hour, an effect that 
persisted for 48 hours. Again addressing functional relevance, endothelial cells 
demonstrated a 44% reduction in a transfected reporter gene under miR-223 control 
when incubated with MPs. Significant downregulation of endogenous RNA levels 
occurred within 6 hours of exposure to platelet MPs, an effect that was rescued with 
the addition of an miR-223-neutralizing sponge.17 
Pan et al91 also showed increased MP release and MP miRNA enrichment after 
platelet activation. In the apolipoprotein E-null mouse model of atherosclerosis, MP 
miR-223 content was higher than in controls. This finding was also tested in a small 
selection of humans, in whom miR-223 expression was found to be higher in platelets 
and MPs of patients with inflammatory diseases compared with healthy controls. The 
authors demonstrated that endothelial cells take up MPs in an ATP-dependent 
manner, and endothelial miR-223 levels increase without an increase in pre-miR-223, 
suggesting that the increase was not because of de novo synthesis in recipient cells. 
Both an miR-223 mimic and incubation with MPs were shown to reduce insulin-like 
growth factor 1 receptor protein levels. This effect was blocked by anti-miR-223. miR-
223 delivery increased advanced glycation end products–induced apoptosis, 
potentially via reduced levels of the insulin-like growth factor 1 receptor.91 
Finally, Gidlöf et al67 showed that patients with ST-segment–elevation myocardial 
infarction had reduced levels of miR-22, miR-185, miR-320b, and miR-423-5p in 
platelets compared with controls and an even greater reduction in aspirated coronary 
artery thrombus. The authors concluded that this is because of platelet activation and 
miRNA release. In vitro, they demonstrated miR-22, miR-185, miR-320b, and miR-
423-5p release into the supernatant after thrombin-induced platelet activation. Using 
platelets transfected with a scrambled, fluorescently labeled miRNA, they showed 
effective transfer to endothelial cells when incubated with activated platelets. 
Furthermore, this was shown to be MP-dependent because the addition of brefeldin A 
(a vesicle formation inhibitor) prevented miRNA transfer. Overexpression of miR-22 
and miR-320b in endothelial cells suggested that these miRNAs were involved in the 
regulation of intercellular adhesion molecule 1. When endothelial cells were incubated 
with platelet releasate, intercellular adhesion molecule 1 expression was 
downregulated by 30%. Knockdown of endogenous endothelial miR-22 and miR-320b 
caused an increase in intercellular adhesion molecule 1 expression, confirming that 
the effect was because of MP miR-22 or miR-320b. Interestingly, this could be rescued 
by incubating the cells with platelet releasate. 
In summary, there is now good evidence that (1) platelets transfer miRNAs and (2) 
that this is mediated by MPs.92,93 However, it is less certain whether this transfer is 
functionally relevant at physiological concentrations in vivo and to what extent the 
observed effects are mediated by the miRNA content rather than the protein content 
of the platelet MP material. Although most studies have focused on platelet transfer of 
miRNA to endothelial cells, Risitano et al71 showed that RNA transfer can occur 
between circulating platelets and monocytes. 
Guidance on How to Measure Circulating miRNAs 
Research on circulating miRNAs is attracting increasing attention because noncoding 
RNAs may constitute an entirely new entity of biomarkers. A prerequisite for advances 
in this area is the generation of comparative data by independent groups. To help this, 
we have suggested a set of minimum-reporting standards and recommended methods 
for circulating miRNA data (Table). 
Plasma or Serum? 
A fundamental question is the choice of plasma or serum for measuring miRNAs 
(Figure 4). The origin of miRNAs in plasma and serum may not be the same because 
platelets are activated during clotting and may contribute a larger proportion of 
miRNAs to serum compared with plasma. In plasma, the cells are removed by 
centrifugation in the presence of an anticoagulant. Citrate and EDTA are the preferred 
anticoagulants. Heparin plasma, for the reasons outlined below, is less suitable for 
miRNA measurements. Platelet activation during plasma centrifugation is another 
concern. Serum, on the other hand, is obtained by clotting blood at room temperature 
for 30 minutes to 1 hour. The clotting process involves the activation of thrombin, which 
cleaves fibrinogen to fibrin. Thrombin is a protease and its substrate specificity is not 
restricted to fibrinogen. The coagulation cascade involves a series of proteases, which 
may degrade carrier proteins of miRNAs. This might result in a loss of miRNAs, which 
can be mitigated by adding RNase inhibitors.94 If platelets release miRNAs on 
activation, then findings in plasma and serum might give opposite results: plasma 
miRNAs may reflect the platelet release prior to blood sampling, whereas serum 
miRNAs may reflect the extracellular and platelet miRNA content combined—the more 
the release, the less the content. Thus, for our most recent studies, we used PPP to 
link miRNAs to in vivo platelet activation.32,34  
Platelets, Microvesicles, and Exosomes 
An understanding of which specific fraction of the circulation is being measured is of 
the utmost importance for reproducibility and adequate interstudy comparison. Ideally, 
one would be able to easily separate different circulating compartments: the cellular 
compartments (erythrocytes, leukocytes, and platelets), the microvesicle 
compartment, the exosome compartment, and the particle-free compartment devoid 
of membrane-bound vesicles or cells. Although isolating erythrocytes and leukocytes 
is relatively easy based on their size and density, isolating the smaller and less dense 
compartments poses a greater challenge. Isolating platelets from PRP is done 
routinely but requires care to avoid activating the platelets during the early 
centrifugation steps. As platelets release microvesicles on activation, this could affect 
the measured miRNAs in platelets, as well as plasma. 
Residual Platelets 
Platelets contain a substantial amount of miRNAs and are likely to be major 
contributors to the circulating miRNA pool, as discussed earlier.34 This further 
complicates sample preparation for miRNA analysis: differences in plasma 
preparation, centrifugation speed, duration of coagulation, and the residual platelet 
content will have an impact on multiple miRNAs.95,96 In RNA extracts from plasma 
samples, the detection of the platelet- and megakaryocyte-specific transcript integrin 
α-IIb can be used to assess platelet content. Notably, the expression of integrin α-IIb 
correlates with the expression of abundant platelet-derived plasma miRNAs (miR-24, 
miR-126, miR-191, and miR-223). If plasma samples have a high residual platelet 
content, their miRNA profile may be more similar to that of serum and reflect 
predominantly platelet miRNA content rather than platelet miRNA release. Plasma 
platelet content must be uniform to allow comparisons between samples because 
residual platelets may introduce confounding. When plasma samples have already 
been collected, an additional centrifugation prior to RNA extraction may reduce the 
platelet content.95 However, centrifugation of plasma after freezing is still subject to 
the risk of contamination from platelets lysed during the freeze/thaw cycle. Ideally, a 
method for the preparation of PPP prior to storage should be used to minimize the 
effect of residual platelets on miRNA measurements. 
Hemolysis 
Erythrocytes are the most abundant cell type in blood. The rupture of erythrocytes can 
occur because of high shear forces in the needle during blood collection or improper 
handling during sample processing. Because hemolytic samples contain a high 
amount of red blood cell–derived miRNAs, the levels of multiple miRNAs are altered 
in hemolytic samples.97 Hemolysis can be assessed in plasma and serum by 
measuring hemoglobin spectrophotometrically or in the respective RNA extracts by 
analyzing miRNAs known to be affected by hemolysis, such as miR-451.98 It is 
advisable to exclude hemolytic samples from further analyses. Alternatively, such 
compromised samples can only be used for miRNAs of interest that are unaffected by 
hemolysis.99 
Leukocyte Contamination 
Cells shed miRNAs via MPs and exosomes into the extracellular space. The miRNA 
content of the MPs and exosomes differs depending on the stimulus of the parent 
cells. However, the intracellular concentration of miRNAs is much higher than that in 
plasma or serum. Considering the low concentration of extracellular, circulating 
miRNAs, any contamination of plasma or serum samples with cellular material, for 
example, leukocytes, will greatly affect the miRNA profile. Thus, studies reporting a 
surprisingly large number of circulating miRNAs compared with other publications may 
have analyzed samples that were contaminated with cellular material. 
Batch Effects 
Batch effects can occur when analyzing the expression of miRNAs on multiple qPCR 
plates. To minimize their effect, several precautions should be taken to obtain reliable 
data: (1) to correct for variability between plates, a calibrator sample should be 
included across all plates. (2) The same batch of plasticware and reagents, such as 
PCR Mastermix, primers, and probes should be used for the entire study cohort. We 
have previously observed lot-to-lot-variability for miRNA reagents, even from leading 
manufacturers. (3) Reagents should be aliquoted because freeze-thaw cycles affect 
their quality and performance. (4) Samples from different groups should be distributed 
equally across all batches. These precautions minimize the effect of batch effects and 
help to obtain more reliable data. 
Endogenous Normalization Controls 
Normalization procedures should eliminate technical and experimental variation 
across samples to more reliably identify biological differences. In qPCR analysis, 
normalization controls are used to correct for variability in RNA extraction, reverse 
transcription, and PCR. Ideally, a normalization control is stably expressed and not 
affected by experimental conditions or clinical parameters. For the analysis of miRNAs 
in cells or tissue, small nucleolar RNAs are routinely used to normalize data. In 
general, they accurately reflect the small RNA content of a sample, although there are 
limitations and drawbacks. For example, small nucleolar RNAs can correlate with 
cancer pathology and prognosis, which can introduce bias when they are used as 
normalization controls for cancer samples.100 For circulating miRNAs, however, there 
is no generally accepted endogenous control. Small nucleolar RNAs are intracellular 
RNA molecules, and their levels in the circulation are very low. U6 RNA has been used 
as a normalization control in plasma and serum samples but circulating levels of U6 
display interindividual variability and are affected by inflammatory processes, reducing 
its reliability.101 Single miRNAs or panels of miRNAs have been used or suggested as 
endogenous controls: miRNAs that have been used as normalizers include miR-16, 
miR-21, miR-93, miR-103, miR-191, miR-192, miR-423, and miR-425. These miRNAs, 
however, may well be affected by other uninvestigated diseases or medications. 
Antiplatelet therapy, for example, has been demonstrated to lower the circulating 
levels of plasma-derived miRNAs, including miR-21 and miR-191.34 Alternatively, data 
can be normalized to the average Ct of multiple or all analyzed miRNAs.102 Generally, 
combinations of miRNAs may be a more robust approach, based on the assumption 
that overall miRNA expression is stable and not affected by disease to the same 
degree as individual miRNAs. The more miRNAs that are combined, the more robust 
the control should be. However, this normalization method can be problematic when 
several of the miRNAs used to normalize are dysregulated in a similar direction, 
potentially causing false-positive or false-negative findings. Nonetheless, accepting 
that no better alternatives exist, a combination of miRNAs represents the most 
stringent endogenous normalization control. 
Exogenous Normalization Controls 
The most commonly used exogenous normalization method for circulating miRNA 
analysis is the use of a spike-in control. For this purpose, synthetic oligonucleotides of 
miRNA sequences from other species are used, typically from the 
nematode Caenorhabditis elegans (eg, cel-miR-39). Such spike-in controls are added 
in equal amounts to each sample during RNA extraction or reverse transcription. A 
spike-in control added at the RNA extraction step can normalize for differences in 
extraction efficiency, reverse transcription, or qPCR efficiency, which may be caused 
by the presence of inhibitors in the sample or pipetting errors. Spike-in controls 
generally reflect miRNA quantities in different samples, but we have observed that 
RNA samples display a lower quantity of cel-miR-39 when they were stored at −80°C 
for a longer period of time, impairing analysis in older samples. Moreover, heparin 
medication can affect cel-miR-39, as well as the measurement of miRNAs, depending 
on their origin.103,104 The cel-miR-39 measurements across samples must be stable. 
Variability exceeding 0.5 to 1 Ct values should be cause for concern. 
MiRNA Measurements 
The gold standard for miRNA measurements is qPCR. It provides independent and 
robust amplification and quantitative detection of minute RNA amounts across the 
wide dynamic range of miRNA expression levels. Among the drawbacks of the 
technology is the fact that its high-throughput capabilities are limited. We have 
previously compared commercial qPCR assays and obtained good agreement 
between assays from 2 suppliers, for individual Taqman miRNA assays and 
customized qPCR plates from Exiqon. For customized qPCR plates, however, there 
is the possibility that variations in the manufacturing process remain undetected. This 
is less likely to occur in standard miRNA assays because multiple users will rapidly 
detect manufacturing problems. Thus, it is important to know the expected 
measurement range for miRNAs of interest when using customized qPCR plates and 
to compare the results from each batch of customized qPCR plates with individual 
qPCR assays. 
We and others have noted difficulties comparing miRNA measurements from different 
technologies. In particular, there is poor agreement between microarrays and qPCRs 
when assessing quantitative changes. Microarray-based technologies use 
hybridization and are suitable for detecting the presence of miRNA species, but have 
limited quantitative accuracy and dynamic range. Similarly, NGS has several 
drawbacks, in particular, requiring much larger sample volumes than qPCR analysis 
and the introduction of amplification bias for certain miRNAs during library preparation. 
For example, in our study, we obtained most reads for miR-486, a miRNA that is 
present in the circulation but has a relatively high Ct value by qPCR, suggesting that 
it is much less abundant than other circulating miRNAs. Thus, miRNAs with more 
sequencing reads are not necessarily more abundant (Figure 5). Quantitative 
comparison must only be made by comparing sequencing reads for the same miRNAs. 
Freedman et al used high-throughput microfluidic quantitative PCR to analyze the 
miRNA signature in blood (whole blood, platelets, mononuclear cells, plasma, and 
serum) collected from 5 healthy individuals. They screened for 852 miRNAs in 83 
patients undergoing diagnostic coronary angiography and categorized their patients 
into 2 groups: with coronary artery stenosis ≥70% (n=34) and without (n=49). 
Increased plasma levels of miR-494, miR-769-3p, and miR-490-3p were associated 
with ≥70% coronary stenosis, and logistic regression analysis found that 
antihypertensive therapy, smoking, and miR-769-3p were significantly associated with 
coronary status.105 In this study, few of the commonly reported highly expressed 
miRNAs were amongst the top 10 ranking miRNAs in platelets (Figure 3). It is likely 
that there are similar discrepancies with plasma and serum miRNA measurements. 
One cause for this difference may be the high-throughput BioMark Real-Time Fluidigm 
PCR system used in this study to increase the number of miRNA measurements that 
can be performed simultaneously; no direct comparison with conventional qPCR was 
provided. 
Potential for Clinical Translation 
The miRNA biomarker field is currently nascent. Although there is much to link the 
expression of miRNAs to various diseases, the clinical utility or validity of miRNA 
detection has not been demonstrated. Currently, miRNAs are manually extracted, 
presenting the largest obstacle to increasing throughput. If new technological 
platforms provide the opportunity for faster miRNA extraction or direct analysis of 
miRNAs without the need for miRNA extraction, they will significantly improve the 
ease-of-use in clinical settings. Increasing throughput, however, must not compromise 
the quantitative accuracy of the analysis for both low- and high-abundance miRNAs. 
Ideally, miRNA measurements need to be able to outperform current diagnostic 
methods to reach the clinical mainstream. 
In addition to current practical limitations, miRNA biomarkers will also need to be 
presented in the context of related miRNAs to be adequately interpreted. There are 
relatively few tissue-specific miRNAs, with miR-122 being an exception given its 
exquisite liver specificity.106 We have recently shown that high circulating miR-122 
levels are associated with an adverse lipid profile and predict development of 
metabolic syndrome and diabetes mellitus type 2.107 However, most circulating 
miRNAs are ubiquitously expressed, and numerous cell types can release miRNAs. 
This complicates the clinical application because levels of individual miRNAs can 
greatly vary between patients, without any pathological significance. Therefore, it is 
crucial to represent relative expression levels of a miRNA in relation to a network of 
several other miRNAs. The use of a so-called miRNA signature can greatly strengthen 
the predictive and diagnostic value. 
Because the origin of many plasma miRNAs is unknown, De Rosa et al108 investigated 
transcoronary gradients of various miRNAs in patients with acute coronary syndrome 
in a bid to define coronary-specific changes in the setting of myocardial damage. 
Samples were taken from the aorta and coronary sinus. They found an upregulation 
of the muscle-enriched miR-499, miR-133a, and miR-208a in acute coronary 
syndrome patients, of which miR-499 correlated with troponin levels, an established 
clinical marker of myocardial damage. Contrary to their predictions, miR-126 
decreased across the coronary circulation, despite its high expression in endothelial 
cells. They also described a negative trend for miR-223 across the coronary circulation 
in the acute coronary syndrome group but not in the stable coronary artery disease 
group; however, this did not reach statistical significance.108 An alternative explanation 
for the reduction in miR-126 and miR-223 across the coronary circulation is the 
retention of platelets and platelet MPs in the affected myocardium or differential 
activation of platelets in venous and arterial settings. 
Pharmacological inhibitors can be used to identify the cellular origins of miRNAs. By 
comparing plasma miRNA levels in the same individuals before and after initiation of 
antiplatelet therapy, we identified a set of plasma miRNAs that is responsive to 
antiplatelet therapy.34 The miRNA candidates were abundant in platelets, but they 
were not platelet-specific. Moreover, not every abundant platelet miRNA was equally 
affected by antiplatelet medication. Some miRNAs, despite their abundance in 
platelets, may be expressed at higher levels in other cell types. Consequently, their 
plasma levels may be less dependent on platelets. Given the platelet origin of many 
abundant circulating miRNAs, it is not surprising that the same miRNAs are 
dysregulated in multiple diseases. The question, however, remains whether the 
circulating miRNA changes are cause or consequence. In cancer, for example, many 
of the circulating miRNA alterations may be because of platelet activation or 
inflammation, rather than the release of miRNAs from tumor tissue. 
Early studies compared platelet samples from different individuals. Longitudinal 
sampling eliminates interindividual variability. For example, using serial 
measurements before and after antiplatelet medication, we investigated the effect of 
10 mg prasugrel followed by the addition of an escalating aspirin dose regimen (75 
mg daily in week 2 and 300 mg daily in week 3) on the PPP miRNA signature of healthy 
young volunteers. Using custom-made miRNA qPCR plates, 92 targets were 
measured at 4 different time points. Antiplatelet therapy was associated with a 
reduction in plasma miR-223, miR-126, miR-15, miR-191, miR-20b, miR-21, and miR-
24. The findings were replicated in plasma of patients with recent symptomatic carotid 
atherosclerosis who had begun treatment with dipyridamole or clopidogrel, in addition 
to aspirin. These patients showed a reduction in miR-223, miR-126, miR-150, and 
miR-191.34 The effect was less pronounced, presumably because the symptomatic 
patients were on aspirin medication at baseline and the follow-up measurement was 
only taken after 48 hours. The reduction in platelet miRNAs on platelet inhibition 
complements previous findings by Zampetaki et al75 in an ischemia/reperfusion injury 
model by thigh cuff inflation, in which plasma miRNAs increased on platelet activation. 
The clinical use of platelet function tests is limited at present, despite clear differences 
in response to pharmacological platelet inhibition. In the case of clopidogrel, a prodrug, 
a large percentage of this variation can be attributed to different cytochrome P450 
isoforms involved in its bioactivation.109 However, this in itself does not explain all of 
the variation in efficacy. Measurements of platelet activity by light transmission 
aggregometry are considered the gold standard, but this test is performed ex vivo and 
not well standardized between laboratories. Vasodilator-stimulated phosphoprotein 
(VASP) phosphorylation and VerifyNow P2Y12 assays measure platelet activation in 
full blood but only in response to a single pathway, ADP stimulation. Platelet miRNAs 
may offer an opportunity to obtain an alternative read-out for platelet activation in vivo 
that integrates activation by multiple agonists rather than just ADP (Figure 6). Platelet 
miRNA measurements, however, will only be useful if they provide diagnostic 
advantages. They also must be easy to perform and capable of discriminating the 
degree of interindividual variability in platelet inhibition or platelet turnover. 
Conclusions 
Initially, circulating miRNAs were thought to originate from tissue injury. This is indeed 
the case for cardiac miRNAs that are released after myocardial infarction akin to 
troponins. For basal miRNA levels, however, the importance of circulating cells is now 
apparent, and the contribution from anucleate cells such as erythrocytes and platelets 
must not be underestimated. Several challenges face the accurate detection and use 
of plasma and serum miRNAs: 
1. Variability in samples’ cell composition affect miRNA profiles. This includes 
anuclear cells such as erythrocytes and residual platelets. Preanalytic variation in 
sample preparation or handling must be minimized to avoid alterations of results. 
Given the platelet origin of many abundant circulating miRNAs, the use of PPP 
would seem to be an appropriate substrate for miRNA measurements. In 
conventional plasma samples, the number of residual platelets can vary. Also, 
without inhibitors, platelet activation may occur during centrifugation. In serum, the 
stability of miRNAs may be affected, and miRNAs may get trapped in the clot. This 
could introduce bias that affects results, in particular, if the clotting time varies 
between sampling. 
2. The concentration of extracellularly circulating miRNAs is low, and the miRNA 
yield of plasma and serum is insufficient for conventional quality control methods, 
such as optical densitometry or Bioanalyzer. Generally, equal volumes of plasma 
or serum are used for extraction. No correction is performed for RNA content. This 
approach of normalizing by volume is, however, analogous to protein 
measurements. In both cases, the total RNA or total protein amount of plasma or 
serum would not be a suitable normalization control for the miRNA or protein 
biomarker of interest. 
3. Currently, there is no endogenous control for the normalization of circulating 
miRNAs. Instead, exogenous spike-in controls are used for normalizing the 
extraction procedure. The values of spike-in controls such as cel-miR-39 relate 
entirely to the consistency of the isolation procedure, not to the starting RNA 
quantity. By measuring a broader panel of unrelated miRNAs, the mean Ct value 
can be used for normalization. 
4. Circulating miRNAs are highly correlated. Assessing individual miRNAs without 
integration into a wider miRNA network is of limited utility. Relative changes in 
miRNAs to one another (so-called miRNA signatures) can be more informative 
than the changes of individual miRNAs. 
These points will need to be addressed in future publications on miRNA biomarkers to 
facilitate comparability between studies, something that has been difficult with 
variations between measurement platforms and lack of guidelines for standardization. 
Standardized miRNA measurement platforms are currently under development, which 
could reduce measurement variability, while facilitating cross-study comparisons. In 
addition to the need for consensus on sample preparation and analytic procedures, 
future research will need to move on from reporting on single miRNAs and focus more 
on miRNA signatures and integration with predicted target genes.77,107,110 These 
issues are not insurmountable, and once addressed, future studies can further 
evaluate the potential of miRNA biomarkers for clinical use and whether miRNA 
assays will outperform existing clinical measurements. 
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Table 1. Minimum reporting standards and methodological recommendations 
for the analysis of circulating miRNAs. 
 
Minimum reporting 
standards Recommendations 
1. Phlebotomy protocol  
Sample venous blood using butterfly or regular blood 
collection needle; standardize relevant pre-analytical 
variables (e.g. fasting, smoking, exercise) 
2. Anticoagulant used Use citrate or EDTA; avoid heparin due to interference with qPCR   
3. Time until 
processing 
Complete sample processing within 2 hours from 
sampling to minimize variability and degradation 
4. Sample processing 
Perform an initial soft spin to collect plasma, followed 
by a faster platelet depletion spin with added inhibitors 
of platelet activation. 
5. Sample storage Store samples at -80°C, avoiding freeze-thaw cycles prior to analysis. 
6. RNA protocol 
Use a validated miRNA or total RNA extraction kit; use 
a carrier (MS2 protein or glycogen); avoid potential 
batch effects by co-isolating RNA from across 
compared groups. 7. miRNA 
measurement 
platform 
Avoid batch effects of different technical lots for used 
laboratory material and equipment 
8. Average Ct levels 
for each assay 
Assays with an average Ct value >32 (when using a 
40-cycle protocol) should be avoided. Report average 
values to facilitate adequate interpretation of presented 
fold changes. 9. Variability of the 
normalization 
reference 
Across-sample variability of quality control markers 
such as an exogenous spike-in miRNA should be no 
more than 1-2 PCR cycles 
10. Normalization 
method(s) 
Normalize to the average Ct value of multiple assays or 
to an exogenous spike-in control. 
 
Figure legends  
Figure 1. Overview of non-coding RNAs in platelets. Although platelets are 
anucleate, they contain genetic material in the form of non-coding RNAs. These 
include small non- coding RNAs, such as microRNAs (miRNAs) and YRNA 
fragments as well as long non- coding RNAs, such as circular RNAs (circRNAs). 
Secondary structures of RNA sequences were predicted using RTips.  
Figure 2. Small non-coding RNAs in plasma. A) Two peaks corresponding 
to miRNAs and YRNAs were observed by small RNA sequencing in plasma. B) 
Correlation of YRNA fragments to plasma levels of platelet factor 4 (PF4), pro-
platelet basic protein (PPBP), and P-selectin (SELP). Lipocalin 2 (LCN2) was 
used as control. N=667.  
Figure 3. Platelet miRNA levels. Relative abundance of miRNAs in platelets 
were reported in 8 studies (indicated by first author). The 50 highest ranking on 
average are presented here, indicating marked variation between different 
studies for the miRNAs beyond the top- 10.  
Figure 4. Choice of samples. A) Workflow for the preparation of PPP from 
PRP. Addition of prostacyclin inhibits platelet activation during centrifugation. 
B) Concerns with regards to miRNA measurements in the different samples 
range from a contamination with leukocytes in PRP, proteolytic activity in serum 
to residual platelets in plasma. PRP and serum should reflect platelet miRNA 
content; PPP platelet miRNA release; plasma samples may reflect either, 
platelet miRNA content or release, depending on the amount of residual 
platelets in the plasma samples or platelet activation during plasma preparation, 
in particular during centrifugation.  
Figure 5. Discrepancy between miRNA quantitation by RT-qPCR and RNA 
sequencing. Average expression of 92 miRNAs was assessed in platelet-poor 
plasma from healthy subjects (n=12), using custom-made Exiqon LNA qPCR 
plates. Cycle-to-threshold (Ct) values are shown as 40-Ct (x-axis). Small RNA 
sequencing was performed with platelet- poor plasma from healthy subjects 
(n=2). miR-486-5p is highlighted, showing high sequencing reads (y-axis) 
despite inferred mid-range abundance by qPCR.  
Figure 6. MiRNAs and platelet reactivity. Association of miR-126 and miR-
223 levels in PPP to the Verify Now P2Y12 aggregation test (A) and the VASP 
phosphorylation assay (B) in patients on dual anti-platelet therapy for 30 days 
post acute coronary syndrome. Note that fewer samples were measured with 
the Verify Now (n=39) compared to the VASP assay (n=123). PRU, denotes 
P2Y12 Reaction Units (x-axis). Higher PRU values reflect higher P2Y12-
mediated platelet reactivity.  
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MicroRNAs 
 
¾ 22-23 nucleotides in length 
¾ >200 miRNAs in platelet-poor plasma 
¾ Regulate mRNA translation 
microRNA-126 
Circular RNAs 
 
¾ Back-splicing of exons 
¾ Originate from RNA decay 
¾ May act as miRNA sponges 
LPAR circular RNA 
Y-RNAs 
 
¾ 4 Y-RNA genes 
¾ Essential for DNA transcription 
¾ Linked to cell stress and apoptosis 
¾ 32-33 nucleotides length fragments 
are detected in plasma 
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